Alt Atlas Ltd.

The company is creating a machine learning software platform that optimizes the R&D and industrial production of novel ingredients and solutions for the alternative meat and dairy industry.

In the first semester of 2022 Alt Atlas team built an ecosystem for success: participated in 2 accelerator programmes, received 2 investments, incremented the company’s valuation in +2.5X, signed +6 LOIs with cultivated meat B2C and B2B technology partners (for pilots, data gathering and co-developments), concluded 2 POCs and filed a provisional patent in the US (for the AI software and the stem cell reprogramming strategy). Currently, the company is actively fundraising, seeking USD2.5M.

After almost a decade, only 4% of cultivated meat companies have reached pilot scale and none industrial scale. Cell lines are the main building block of cultivated meat. Of the available cell lines at GFI (The Good food Institute) repository, only 1 has the potential to produce meat. However, none is commercially viable.
As a start, Alt Atlas is solving the problem of cell lines unavailability and cultivated meat production scalability.

Alt Atlas delivers stem cell lines door-to-door (non-GMO bovine stem cell lines optimized for food application) and scale-up services in the cloud (store users’ data, manage experiments information, access custom made reports providing recommendations to improve users’ cell culture conditions based on AI allowing for higher cell biomass at various scales).

B2B model. For the cultivated meat services: Alt Atlas will enter the market next year, selling to customers we have already identified (fixed fee). By 2025, our cells and expertise will enable 15 customers to reach pilot scale, having 8M in revenues (subscription model). By 2030, with our help 130 customers will reach cost parity with conventional animal meat, allowing us to reach $210M in revenues. By then, the cultivated meat market is projected to be worth $25B (McKinsey)

Brinc - Hong Kong
Big Idea Ventures- NYC